Harvard Bio's Q4 Revenues Rise 22 Percent as R&D Swells and Losses Narrow | GenomeWeb
NEW YORK (GenomeWeb News) — Harvard Bioscience yesterday said fourth-quarter revenue rose 22 percent as R&D spending increased 17 percent, and losses narrowed by 75 percent.
Total receipts for the three months ended Dec. 30, 2006, increased to $21.7 million from $17.8 million year over year.
 
The company said revenue grew “across various product lines,” but was mainly due to greater demand for physiology and cell-biology equipment, “particularly in Asia Pacific and in Europe.”
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: a sequencing-based screen of Lyme disease-causing pathogen, the range of animals bitten by Anopheles darling mosquitoes in Peru, and more.

An NC State researcher is exploring the use of CRISPR-Cas3 as an anti-microbial, Gizmodo reports.

The Earth BioGenome Project plans to sequence all life on Earth, according to ScienceInsider.

For those who are concerned about Trump administration actions related to science, a new column in Scientific American has suggestions for ways to fight back.